Skip to main content

Day: September 29, 2023

Calian Launches Digital Health Portfolio of Products and Services

OTTAWA, Sept. 29, 2023 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY), a diverse products and services company providing innovative healthcare, communications, learning and cybersecurity solutions has announced the addition of a Digital Health portfolio to its existing Health Solutions division. Calian’s Digital Health division was established to better capture opportunities across the evolving healthcare landscape and to better serve Calian’s growing client-base. The Digital Health portfolio delivers services and award-winning software applications which improve access to high-quality care, while transforming the patient and care provider experience. “For more than 13 years, we’ve delivered world-class healthcare solutions to clients across Canada,” says Kevin Ford, Calian CEO. “Our digital solutions create seamless connections...

Continue reading

New Pacific Metals Closes C$35 Million Bought Deal Financing

VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) — New Pacific Metals Corp. (TSX: NUAG; NYSE American: NEWP) (“New Pacific” or the “Company”) announced today that it has closed (the “Closing“) the bought deal financing that was previously announced on September 25, 2023. A total of 13,208,000 common shares of the Company (the “Offered Shares”) were sold under the Offering (as defined below) at a price of C$2.65 per Offered Share (the “Issue Price”) for total gross proceeds of approximately C$35 million (the “Offering”). The Offering was through a syndicate of underwriters (the “Underwriters”), pursuant to the terms of an underwriting agreement between the Company and the Underwriters dated September 26, 2023 (the “Underwriting Agreement“). Silvercorp Metals Inc. (“Silvercorp”) participated in...

Continue reading

New Pacific Metals Closes C$35 Million Bought Deal Financing

Not for Distribution in the United States or to U.S. Newswire Services VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) — New Pacific Metals Corp. (TSX: NUAG; NYSE American: NEWP) (“New Pacific” or the “Company”) announced today that it has closed (the “Closing“) the bought deal financing that was previously announced on September 25, 2023. A total of 13,208,000 common shares of the Company (the “Offered Shares”) were sold under the Offering (as defined below) at a price of C$2.65 per Offered Share (the “Issue Price”) for total gross proceeds of approximately C$35 million (the “Offering”). The Offering was co-led by Raymond James Ltd. and Eight Capital (together, the “Co-Lead Underwriters”), on behalf of a syndicate of underwriters (collectively with the Co-Lead Underwriters, the “Underwriters”), pursuant...

Continue reading

Portage Biotech Announces $6.0 Million Registered Direct Offering

WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) — Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.90 per share (or common stock equivalent in lieu thereof). The Company has also agreed to issue in a concurrent private placement unregistered series A warrants to purchase up to an aggregate of 3,157,895 shares of common stock, series B warrants to purchase up to an aggregate of 3,157,895 shares of common stock and series C warrants to purchase up to an aggregate of 3,157,895...

Continue reading

Baker Hughes Strengthens Norway Presence with 2 Major Contracts from Vår Energi

Transformative nine-year contract enhances well intervention and exploration logging services for Vår Energi Second order includes advanced subsea production systems Two contracts with Vår Energi significantly reinforce Baker Hughes’ industry leadership and growth trajectoryHOUSTON and LONDON, Sept. 29, 2023 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Friday two awards from Vår Energi that expand its regional presence in the North Sea for exploration logging, well intervention technology and subsea production systems. The first contract, a nine-year engagement, is a testament to Baker Hughes’ heightened well intervention capabilities gained through the strategic acquisition of Altus Intervention completed in April 2023. In addition to the interventions scope, Baker Hughes will supply...

Continue reading

Mobiv Acquisition Corp Stockholders Approve Previously Announced Business Combination with SRIVARU Holding Limited

Transaction anticipated to close upon satisfaction of all closing conditions Newark, DE, Sept. 29, 2023 (GLOBE NEWSWIRE) — Mobiv Acquisition Corp (Nasdaq: MOBVU, MOBV, MOBVW) (“Mobiv” or the “Company”), a special purpose acquisition company, today announced that Mobiv stockholders voted to approve the previously proposed business combination with SRIVARU Holding Limited, a Cayman Islands exempted company (“SRIVARU”), a commercial-stage provider of premium electric motorcycles, at Mobiv’s special meeting of stockholders held yesterday, September 28, 2023 (the “Special Meeting”). The business combination is being implemented pursuant to the Agreement and Plan of Merger dated March 13, 2023, by and among Mobiv, SRIVARU, and Pegasus Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of SRIVARU (“Merger Sub”), as amended...

Continue reading

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA) Granted orphan drug designation from the European Commission for treatment in hematopoietic stem cell transplantation, adding to existing FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations The company established a Boston U.S. headquarters office to support expanding operations and the start of registrational Phase 3 clinical trials Strengthened capabilities with appointment of Beth-Anne Lang, an experienced executive with a long track record of successful regulatory approvals, as Senior Vice President, Regulatory Affairs, and industry veterans Wa’el Hashad as independent director and Wendy DiCicco...

Continue reading

Jianzhi Education Technology Group Company Limited Reports Fiscal Year 2022 Financial Results

BEIJING, Sept. 29, 2023 (GLOBE NEWSWIRE) —  Jianzhi Education Technology Group Company Limited (the “Company” or “Jianzhi”) (NASDAQ: JZ), a leading provider of digital educational content in China, today announced its financial results for fiscal year 2022. Yong Hu, CEO of the Company commented: “In the fiscal year 2022, we remained committed to meeting China’s demand for high-quality vocational training resources and solidified our position as a leading digital educational content provider in the country. During the year ending December 31, 2022, our company achieved a revenue growth of about 6.9%, reaching approximately RMB505.7 million, compared to about RMB473.2 million in 2021. This growth was primarily driven by a significant increase in revenue from IT related solutions and services, which saw a substantial increase...

Continue reading

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The target action date for the FDA decision is March 31, 2024. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge...

Continue reading

Dovre Group´s Norwegian operations, i.e. Dovre Group Energy and Dovre Group Consulting, have been attacked by ransom virus at one of our servers in Stavanger

Dovre Group Plc                            Press release                 September 29, 2023, at 3.30 pm Dovre Group´s Norwegian operations, i.e. Dovre Group Energy and Dovre Group Consulting, have been attacked by ransom virus at one of our servers in Stavanger We are working closely together with our IT-partner on our contingency plan and are already up and running on safe email and basic office systems. The server involved contains part of our financial systems and operational directories. The impact for our consultants and clients is limited as the majority of our consultants in Norway are working within our clients´ organization, using their IT-systems. Our main challenge is that our internal administration will have an extra burden in the coming period.   It is too early to estimate further economic consequences, focus now is to secure...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.